Skip to main content

Advertisement

SpringerLink
Log in

Currents Concepts on the Immunopathology of Amyloidosis

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Amyloidosis is defined as the extracellular accumulation at systemic or organ-specific level of insoluble low molecular weight protein fibrils manifesting a beta pleated sheet configuration and a characteristic staining pattern. Several different types of proteins may lead to this phenomenon, and amyloidosis is defined by the biochemical nature of the protein in the deposits and further classified according to whether the deposits are localized or systemic, acquired or inherited, and by the resulting clinical phenotype. Amyloidosis includes subtypes such as light chain, associated with serum amyloid A protein, heritable and familial forms, dialysis-related disease, and organ-specific conditions. The pathogenesis and clinical features of these clinical and pathological entities will be critically discussed in this review article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:583–596

    Article  CAS  PubMed  Google Scholar 

  2. Kisilevsky R, Young ID (1994) Pathogenesis of amyloidosis. Baillieres Clin Rheumatol 8:613–626

    Article  CAS  PubMed  Google Scholar 

  3. Gallo G, Wisniewski T, Choi-Miura NH, Ghiso J, Frangione B (1994) Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 145:526–530

    CAS  PubMed  Google Scholar 

  4. Rajkumar SV (2008) Pathogensis and clinical features of primary (AL) amyloidosis and light and heavy chain deposition diseases. In UpToDate online

  5. Husby G, Stenstad T, Magnus JH, Sletten K, Nordvag BY, Marhaug G (1994) Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis. Clin Immunol Immunopathol 70:2–9

    Article  CAS  PubMed  Google Scholar 

  6. Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 92:4299–4303

    Article  CAS  PubMed  Google Scholar 

  7. Kaplan B, Ramirez-Alvarado M, Sikkink L, Golderman S, Dispenzieri A, Livneh A, Gallo G (2009) Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br J Haematol 144:705–715

    Article  CAS  PubMed  Google Scholar 

  8. Gertz MA, Lacy MQ, Dispenzieri A (1999) Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 74:490–494

    Article  CAS  PubMed  Google Scholar 

  9. Rajkumar SV, Dispenzieri A, Kyle RA (2006) Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 81:693–703

    Article  PubMed  Google Scholar 

  10. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R (2003) Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101:3801–3808

    Article  CAS  PubMed  Google Scholar 

  11. Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, Fonseca R, Ketterling RP, Knudson RA, Mulvihill EM et al (2008) Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 112:1931–1941

    Article  CAS  PubMed  Google Scholar 

  12. Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, Phillips SA (2009) Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol (in press)

  13. Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Skinner M, Manning WJ (2009) Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103:544–549

    Article  PubMed  Google Scholar 

  14. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S et al (2009) Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55:499–504

    Article  CAS  PubMed  Google Scholar 

  15. van Gameren I, Hazenberg BP, Bijzet J, van Rijswijk MH (2006) Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 54:2015–2021

    Article  PubMed  Google Scholar 

  16. Ansari-Lari MA, Ali SZ (2004) Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol 30:178–181

    Article  PubMed  Google Scholar 

  17. Bogov B, Lubomirova M, Kiperova B (2008) Biopsy of subcutaneus fatty tissue for diagnosis of systemic amyloidosis. Hippokratia 12:236–239

    CAS  PubMed  Google Scholar 

  18. Kyle RA, Bayrd ED (1975) Amyloidosis: review of 236 cases. Medicine (Baltimore) 54:271–299

    CAS  Google Scholar 

  19. Eder L, Bitterman H (2007) Image in clinical medicine. Amyloid purpura. N Engl J Med 356:2406

    Article  CAS  PubMed  Google Scholar 

  20. Dominguez S, Wienberg P, Claros P, Claros A, Vila J (1996) Primary localized nasopharyngeal amyloidosis. A case report. Int J Pediatr Otorhinolaryngol 36:61–67

    Article  CAS  PubMed  Google Scholar 

  21. Dimopoulos M, Kastritis E (2008) High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further? Leuk Lymphoma 49:4–5

    Article  PubMed  Google Scholar 

  22. Zhou P, Teruya-Feldstein J, Lu P, Fleisher M, Olshen A, Comenzo RL (2008) Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. Blood 111:549–557

    Article  CAS  PubMed  Google Scholar 

  23. Mereles D, Wanker EE, Katus HA (2008) Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol 97:341–344

    Article  PubMed  Google Scholar 

  24. Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, Maurer MS, Steingart RM, Cohen AD, Comenzo RL (2008) Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 143:369–373

    Article  CAS  PubMed  Google Scholar 

  25. Zhou P, Comenzo RL, Olshen AB, Bonvini E, Koenig S, Maslak PG, Fleisher M, Hoffman J, Jhanwar S, Young JW et al (2008) CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 111:3403–3406

    Article  CAS  PubMed  Google Scholar 

  26. Wilson PG, Thompson JC, Webb NR, de Beer FC, King VL, Tannock LR (2008) Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol 173:1902–1910

    Article  CAS  PubMed  Google Scholar 

  27. Wetmore JB, Lovett DH, Hung AM, Cook-Wiens G, Mahnken JD, Sen S, Johansen KL (2008) Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton) 13:593–600

    Article  CAS  Google Scholar 

  28. Westermark GT, Westermark P (2009) Serum amyloid A and protein AA: Molecular mechanisms of a transmissible amyloidosis. FEBS Lett (in press)

  29. Milner J, Ward J, Keane-Myers A, Min B, Paul WE (2007) Repertoire-dependent immunopathology. J Autoimmun 29:257–261

    Article  CAS  PubMed  Google Scholar 

  30. Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28:69–75

    Article  CAS  PubMed  Google Scholar 

  31. Malle E, Sodin-Semrl S, Kovacevic A (2009) Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66:9–26

    Article  CAS  PubMed  Google Scholar 

  32. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361–2371

    Article  CAS  PubMed  Google Scholar 

  33. Westermark GT, Westermark P, Sletten K (1987) Amyloid fibril protein AA. Characterization of uncommon subspecies from a patient with rheumatoid arthritis. Lab Invest 57:57–64

    CAS  PubMed  Google Scholar 

  34. Kluve-Beckerman B, Manaloor JJ, Liepnieks JJ (2002) A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum 46:1905–1913

    Article  CAS  PubMed  Google Scholar 

  35. Tuglular S, Yalcinkaya F, Paydas S, Oner A, Utas C, Bozfakioglu S, Ataman R, Akpolat T, Ok E, Sen S et al (2002) A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 17:2003–2005

    Article  PubMed  Google Scholar 

  36. Momohara S, Okamoto H, Yamanaka H (2008) Chondrocyte of rheumatoid arthritis serve as a source of intra-articular acute-phase serum amyloid A protein. Clin Chim Acta 398:155–156

    Article  CAS  PubMed  Google Scholar 

  37. Ritta Koivuniemi LP, Suomalainen R, Tornroth T (2008) 4Amyloidosis is frequently undetected in patients with rhematoid arthritis. Amyloid 15:262–268

    Article  CAS  Google Scholar 

  38. David J, Vouyiouka O, Ansell BM, Hall A, Woo P (1993) Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 11:85–90

    CAS  PubMed  Google Scholar 

  39. Kelly KJ, Kluve-Beckerman B, Dominguez JH (2009) Acute-phase response protein serum amyloid A stimulates renal tubule formation: studies in vitro and in vivo. Am J Physiol Renal Physiol 296:F1355–F1363

    Article  CAS  PubMed  Google Scholar 

  40. Simms RW, Prout MN, Cohen AS (1994) The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 8:627–634

    Article  CAS  PubMed  Google Scholar 

  41. Singh G, Kumari N, Aggarwal A, Krishnani N, Misra R (2007) Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 34:371–373

    PubMed  Google Scholar 

  42. Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43:227–253

    Article  CAS  PubMed  Google Scholar 

  43. Gertz MA, Kyle RA (1991) Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 70:246–256

    CAS  Google Scholar 

  44. Melikoglu M, Altiparmak MR, Fresko I, Tunc R, Yurdakul S, Hamuryudan V, Yazici H (2001) A reappraisal of amyloidosis in Behcet's syndrome. Rheumatology (Oxford) 40:212–215

    Article  CAS  Google Scholar 

  45. Nakamura S, Morishita M, Yang CL, Utsumi K, Takada H, Furuhashi K, Sugiura H (2006) An elderly female who survived more than 30 years following a diagnosis of Takayasu's arteritis, complicated by fatal intestinal amyloidosis. Clin Rheumatol 25:907–910

    Article  CAS  PubMed  Google Scholar 

  46. Cruz I, Oliveira AP, Lopes JM, Ricardo JL, de Freitas J (1993) Whipple's disease and renal amyloidosis. Am J Gastroenterol 88:1954–1956

    CAS  PubMed  Google Scholar 

  47. Escriba A, Morales E, Albizua E, Herrero JC, Ortuno T, Carreno A, Dominguez-Gil B, Praga M (2000) Secondary (AA-type) amyloidosis in patients with polymyalgia rheumatica. Am J Kidney Dis 35:137–140

    Article  CAS  PubMed  Google Scholar 

  48. Robinson RD, Murphy EL, Wilks RJ, Neva FA, Terry SI, Hanchard B, Figueroa JP, Blattner WA (1991) Gastrointestinal parasitic infection in healthy Jamaican carriers of HTLV-I. J Trop Med Hyg 94:411–415

    CAS  PubMed  Google Scholar 

  49. Guma M, Bayes B, Bonet J, Olive A (1999) Gout and secondary amyloid. Clin Rheumatol 18:54–55

    Article  CAS  PubMed  Google Scholar 

  50. Wong BC, Wong KL, Ip MS, Wang EP, Chan KW, Cheng LC (1994) Sjogren's syndrome with amyloid A presenting as multiple pulmonary nodules. J Rheumatol 21:165–167

    CAS  PubMed  Google Scholar 

  51. Redline S, Pack AI (2006) Rising to meet an unmet public health need: sleep medicine and the pulmonary community. Am J Respir Crit Care Med 174:487–488

    Article  PubMed  Google Scholar 

  52. Van Der Hilst JCH, Drenth JP (2005) Serum amyloid A serum concentratins and genotype do not explain low incidence of amyloidosis in Hyper -IgD syndrome. Amyloid 12:115–119

    Article  PubMed  CAS  Google Scholar 

  53. Picken MM, Pelton K, Frangione B, Gallo G (1987) Primary amyloidosis A. Immunohistochemical and biochemical characterization. Am J Pathol 129:536–542

    CAS  PubMed  Google Scholar 

  54. Jager PL, Hazenberg BP, Franssen EJ, Limburg PC, van Rijswijk MH, Piers DA (1998) Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med 39:699–706

    CAS  PubMed  Google Scholar 

  55. Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323:508–513

    CAS  PubMed  Google Scholar 

  56. Kumar-Singh S (2009) Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models. Int J Mol Sci 10:1872–1895

    Article  CAS  PubMed  Google Scholar 

  57. Eriksson M, Schonland S, Yumlu S, Hegenbart U, von Hutten H, Gioeva Z, Lohse P, Buttner J, Schmidt H, Rocken C (2009) Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn 11:257–262

    Article  CAS  PubMed  Google Scholar 

  58. Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P (2008) Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 216:253–261

    Article  CAS  PubMed  Google Scholar 

  59. Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A, Hawkins PN (2009) Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 20:444–451

    Article  CAS  PubMed  Google Scholar 

  60. Dardiotis E, Koutsou P, Papanicolaou EZ, Vonta I, Kladi A, Vassilopoulos D, Hadjigeorgiou G, Christodoulou K, Kyriakides T (2009) Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus. Amyloid 16:32–37

    Article  PubMed  Google Scholar 

  61. Nagasaka T, Togashi S, Watanabe H, Iida H, Nagasaka K, Nakamura Y, Miwa M, Kobayashi F, Shindo K, Shiozawa Z (2009) Clinical and histopathological features of progressive-type familial amyloidotic polyneuropathy with TTR Lys54. J Neurol Sci 276:88–94

    Article  CAS  PubMed  Google Scholar 

  62. Hornsten R, Suhr OB, Jensen SM, Wiklund U (2008) Outcome of heart rate variability and ventricular late potentials after liver transplantation for familial amyloidotic polyneuropathy. Amyloid 15:187–195

    Article  CAS  PubMed  Google Scholar 

  63. Robin J, Meyers S, Nahlawi M, Puthumana J, Lomasney J, Mehlman D, Rigolin V, Davidson C (2008) Accelerating restrictive cardiomyopathy after liver transplantation in a patient with familial amyloidotic polyneuropathy: a case report. J Med Case Reports 2:35

    Article  PubMed  Google Scholar 

  64. Hou X, Aguilar MI, Small DH (2007) Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 274:1637–1650

    Article  CAS  PubMed  Google Scholar 

  65. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH (1997) Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78:74–82

    CAS  PubMed  Google Scholar 

  66. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336:466–473

    Article  CAS  PubMed  Google Scholar 

  67. Jacobson DR, Ittmann M, Buxbaum JN, Wieczorek R, Gorevic PD (1997) Transthyretin Ile 122 and cardiac amyloidosis in African-Americans. 2 case reports. Tex Heart Inst J 24:45–52

    CAS  PubMed  Google Scholar 

  68. Klein AL, Hatle LK, Taliercio CP, Taylor CL, Kyle RA, Bailey KR, Seward JB, Tajik AJ (1990) Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16:1135–1141

    Article  CAS  PubMed  Google Scholar 

  69. Hawkins PN (2003) Hereditary systemic amyloidosis with renal involvement. J Nephrol 16:443–448

    CAS  PubMed  Google Scholar 

  70. Yazaki M, Liepnieks JJ, Barats MS, Cohen AH, Benson MD (2003) Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int 64:11–16

    Article  CAS  PubMed  Google Scholar 

  71. Maury CP, Sletten K, Totty N, Kangas H, Liljestrom M (1997) Identification of the circulating amyloid precursor and other gelsolin metabolites in patients with G654A mutation in the gelsolin gene (Finnish familial amyloidosis): pathogenetic and diagnostic implications. Lab Invest 77:299–304

    CAS  PubMed  Google Scholar 

  72. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE (2003) Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 10:160–184

    CAS  PubMed  Google Scholar 

  73. Tutaj M, Szczepanik M (2007) Epicutaneous (EC) immunization with myelin basic protein (MBP) induces TCRalphabeta+ CD4+ CD8+ double positive suppressor cells that protect from experimental autoimmune encephalomyelitis (EAE). J Autoimmun 28:208–215

    Article  CAS  PubMed  Google Scholar 

  74. Otsubo S, Kimata N, Okutsu I, Oshikawa K, Ueda S, Sugimoto H, Mitobe M, Uchida K, Otsubo K, Nitta K et al (2009) Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial Transplant 24:1593–1598

    Article  PubMed  Google Scholar 

  75. Kim J, Motomiya Y, Ueda M, Nakamura M, Misumi Y, Saito S, Ikemizu S, Misumi S, Ota K, Shinriki S et al (2008) Role of conformational change in the C-terminus of beta2-microglobulin in dialysis-related amyloidosis. Ann Clin Biochem 45:489–495

    Article  CAS  PubMed  Google Scholar 

  76. Naiki H, Yamamoto S, Hasegawa K, Yamaguchi I, Goto Y, Gejyo F (2005) Molecular interactions in the formation and deposition of beta2-microglobulin-related amyloid fibrils. Amyloid 12:15–25

    Article  CAS  PubMed  Google Scholar 

  77. Koch KM (1992) Dialysis-related amyloidosis. Kidney Int 41:1416–1429

    Article  CAS  PubMed  Google Scholar 

  78. Noel LH, Zingraff J, Bardin T, Atienza C, Kuntz D, Drueke T (1987) Tissue distribution of dialysis amyloidosis. Clin Nephrol 27:175–178

    CAS  PubMed  Google Scholar 

  79. Saito A, Gejyo F (2006) Current clinical aspects of dialysis-related amyloidosis in chronic dialysis patients. Ther Apher Dial 10:316–320

    Article  CAS  PubMed  Google Scholar 

  80. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284:4749–4753

    Article  CAS  PubMed  Google Scholar 

  81. Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ (2009) Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 10:94–100

    Article  CAS  PubMed  Google Scholar 

  82. Gorevic PD (2008) Genetic factos in the amyloid dissseases. In UpToDate online

  83. Lleo A, Berezovska O, Growdon JH, Hyman BT (2004) Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry 12:146–156

    PubMed  Google Scholar 

  84. Tucker SM, Borchelt DR, Troncoso JC (2008) Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease. J Neuropathol Exp Neurol 67:30–40

    Article  CAS  PubMed  Google Scholar 

  85. Olafsson I, Grubb A (2000) Hereditary cystatin C amyloid angiopathy. Amyloid 7:70–79

    Article  CAS  PubMed  Google Scholar 

  86. Kristen AV, Schnabel PA, Winter B, Helmke BM, Longerich T, Hardt S, Koch A, Sack FU, Katus HA, Linke RP et al (2009) High prevalence of amyloid in 150 surgically removed heart valves-a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc Pathol (in press)

  87. Kyle RA (1995) Amyloidosis. Circulation 91:1269–1271

    CAS  PubMed  Google Scholar 

  88. Lewis JE, Olsen KD, Kurtin PJ, Kyle RA (1992) Laryngeal amyloidosis: a clinicopathologic and immunohistochemical review. Otolaryngol Head Neck Surg 106:372–377

    CAS  PubMed  Google Scholar 

  89. Gillmore JD, Hawkins PN (1999) Amyloidosis and the respiratory tract. Thorax 54:444–451

    Article  CAS  PubMed  Google Scholar 

  90. Blank M, Gershwin ME (2008) Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun 30:1–4

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Allergy and Clinical Immunology, Genome and Biomedical Sciences Facility, University of California at Davis School of Medicine, 451 Health Sciences Drive, Suite 6510, Davis, CA, 95616, USA

    Anupama Bhat, Carlo Selmi, Stanley M. Naguwa, Gurtej S. Cheema & M. Eric Gershwin

  2. Department of Translational Medicine, IRCCS-Istituto Clinico Humanitas, Università degli Studi di Milano, Rozzano, Italy

    Carlo Selmi

Authors
  1. Anupama Bhat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlo Selmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stanley M. Naguwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gurtej S. Cheema
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Eric Gershwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Eric Gershwin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhat, A., Selmi, C., Naguwa, S.M. et al. Currents Concepts on the Immunopathology of Amyloidosis. Clinic Rev Allerg Immunol 38, 97–106 (2010). https://doi.org/10.1007/s12016-009-8163-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-009-8163-9

Keywords

Search

Navigation